SGCE promotes breast cancer stemness by promoting the transcription of FGF-BP1 by Sp1

J Biol Chem. 2023 Nov;299(11):105351. doi: 10.1016/j.jbc.2023.105351. Epub 2023 Oct 12.

Abstract

Breast cancer stem cells are mainly responsible for poor prognosis, especially in triple-negative breast cancer (TNBC). In a previous study, we demonstrated that ε-Sarcoglycan (SGCE), a type Ⅰ single-transmembrane protein, is a potential oncogene that promotes TNBC stemness by stabilizing EGFR. Here, we further found that SGCE depletion reduces breast cancer stem cells, partially through inhibiting the transcription of FGF-BP1, a secreted oncoprotein. Mechanistically, we demonstrate that SGCE could interact with the specific protein 1 transcription factor and translocate into the nucleus, which leads to an increase in the transcription of FGF-BP1, and the secreted FBF-BP1 activates FGF-FGFR signaling to promote cancer cell stemness. The novel SGCE-Sp1-FGF-BP1 axis provides novel potential candidate diagnostic markers and therapeutic targets for TNBC.

Keywords: TNBC; breast cancer stem cells; gene transcription; nuclear localization.

MeSH terms

  • Cell Line, Tumor
  • Cell Proliferation
  • Humans
  • Intercellular Signaling Peptides and Proteins / metabolism
  • Neoplastic Stem Cells* / metabolism
  • Sarcoglycans* / metabolism
  • Signal Transduction
  • Sp1 Transcription Factor* / metabolism
  • Triple Negative Breast Neoplasms* / metabolism

Substances

  • Sarcoglycans
  • SGCE protein, human
  • Sp1 Transcription Factor
  • FGFBP1 protein, human
  • Intercellular Signaling Peptides and Proteins